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OBJECTIVE — To estimate the impacts on Medicare costs of providing a particular type of
home telemedicine to eligible Medicare beneﬁciaries with type 2 diabetes.
RESEARCH DESIGN AND METHODS — Two cohorts of beneﬁciaries (n  1,665 and
504, respectively) living in two medically underserved areas of New York between 2000 and
2007wererandomizedtointensivenursecasemanagementviatelevisitsorusualcare.Medicare
service use and costs covering a 6-year follow-up period were drawn from claims data. Impacts
were estimated using regression analyses.
RESULTS — Informatics for Diabetes Education and Telemedicine (IDEATel) did not reduce
Medicare costs in either site. Total costs were between 71 and 116% higher for the treatment
group than for the control group.
CONCLUSIONS — Although IDEATel had modest effects on clinical outcomes (reported
elsewhere), it did not reduce Medicare use or costs for health services. The intervention’s costs
were excessive (over $8,000 per person per year) compared with programs with similar-sized
clinical impacts.
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H
ometelemedicinedeliversmonitor-
ing, educational, and therapeutic
servicestopeoplethroughtelecom-
munications technology. It may be a
promising way to deliver such services to
individuals with poor access to high-
quality care due to language, culture, low
educational attainment, disempower-
ment, and lack of social reinforcement for
healthy behaviors.
The congressionally mandated Infor-
matics for Diabetes Education and Tele-
medicine (IDEATel) tested the clinical
outcomesofprovidingaparticulartypeof
hometelemedicinetoMedicarebeneﬁcia-
ries with type 2 diabetes. A consortium
led by Columbia University implemented
IDEATel in two 4-year phases (February
2000 to February 2008) (1).
RESEARCH DESIGN AND
METHODS
Goals
For phase I, participants aimed to control
blood glucose, high blood pressure, and
abnormal lipid levels and reduce or elim-
inate obesity and physical inactivity. Phy-
sicians aimed to increase guideline-based
diabetes care. For phase II, the consor-
tium addressed phase I lessons learned
and pursued the original goals.
Recruitment
Between December 2000 and October
2002, the Consortium recruited and ran-
domized 1,665 cohort 1 Medicare bene-
ﬁciaries (775 in New York City; 890 in
upstate NY). Subsequently, between De-
cember2004andOctober2005,theCon-
sortium recruited and randomized 504
cohort 2 beneﬁciaries (174 in New York
City; 330 in upstate NY). For both co-
horts, eligibility was limited to beneﬁcia-
ries aged 55 years who were being
treated for diabetes by diet, oral medica-
tions, or insulin; living in a medically un-
derserved or health professional shortage
area in New York state; and English or
Spanish speaking. Poor-health exclusion
criteria also applied. After consenting,
beneﬁciaries underwent an in-person
baseline assessment by Consortium staff.
The Consortium randomly assigned ben-
eﬁciaries in both cohorts, in equal pro-
portions, to a treatment or control group.
The intervention
After randomization, treatment and con-
trol group members continued receiving
diabetescarefromtheirprimarycarephy-
sicians, but treatment group members’
physicians received recommendations
fromtheIDEATeldiabetologistsconcern-
ing the care of participants. Treatment
group members were offered installation
of a home telemedicine unit (HTU) and
training in its use.
For phase I, the HTU was a desktop-
model PC, connected to a regular tele-
phone line, with a monitor, keyboard,
and mouse; video camera; speakers; mi-
crophone; and glucose and blood pres-
sure meters. Participants could use the
HTU components to 1) measure and
monitor blood glucose and blood pres-
surereadings;2)interactwithanIDEATel
nurse case manager, in English or Span-
ish, through scheduled two-way video
conferences; and 3) access web-based ed-
ucationalmaterials.ForphaseII,theCon-
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large size and difﬁculty of use.
Hypotheses
Nurse education and coaching through
televisits and self-tracking of progress
through other HTU functions could have
improved participants’ self-care behav-
iors, adhering to diet, exercise, foot care,
and medication regimes. IDEATel’s
guideline-based recommendations to
physicians could have promoted better
prescribing patterns. These improve-
mentscouldhelpparticipantsavoidlong-
term health complications that could
reduce use of acute care services, primar-
ily hospitalizations, and Medicare costs.
Outcomes
Use of Medicare-covered services and
Medicare costs by type of service, total
Medicare costs for health care services,
and total Medicare costs for both health
care services and the intervention.
Data
The Consortium extracted Medicare
claims without identifying information.
Follow-up data were available for up to 6
years, from randomization through De-
cember 2006. An intention-to-treat anal-
ysis included 1,625 cohort 1 and 491
cohort 2 enrollees with complete data.
Impact estimation
Site-speciﬁc impacts were estimated with
linear regression (ordinary least-squares)
models that controlled for baseline socio-
demographic characteristics, experience
with computers, diabetes control, and a
measureoftheoutcomeinquestion.Out-
comes were annualized and weighted by
their months of enrollment in fee-for-
service Medicare because no claims data
exist for HMO enrollees. The reported
treatment and control group means were
predicted from the coefﬁcients of the es-
timated models.
Demonstration costs
The budget for the demonstration’s ﬁrst
and second phases was $28,159,066 and
$28,812,419, respectively (2). Estimates
oftheintervention’scostsaresummarized
in Table A4 (available in an online-only
appendix at http://care.diabetesjournals.
org/cgi/content/full/dc09-0094/DC1).
RESULTS— Inbothsites,andforboth
cohorts, treatment and control group
members were similar, on average, on all
baseline characteristics, as expected un-
der random assignment (online appendix
Tables A1 and A2). However, enrollees’
characteristics varied by site and cohort.
Only for cohort 1 were mean annual
total Medicare Part B expenditures signif-
icantly higher (13% of the control group
mean; P  0.025) for treatment group
membersthanforcontrolgroupmembers
in upstate New York (Table 1).
Total intervention costs were $8,924
and$8,437perpersonperyearforphases
I and II, respectively. The costs during
phase II were lower than during phase I
because the costs were spread over a
longer period.
The savings in total Medicare expen-
ditures in any site or cohort were either
nonexistent or too small to offset the high
costsoftheintervention.Totalper-person
costs were between $9,500 and $9,800
higher for treatment group than for con-
trol group members for cohort 1 and
$6,200 to $8,700 for cohort 2 (P 
0.001).
Thestudyislimitedbecauseitcannot
Table 1—Estimated annual per-person expenditures for Medicare-covered services, intervention-related costs, and costs for total services, by
site, evaluation group, and cohort
New York City Upstate New York
Treatment
group
Control
group Difference (P)
Treatment
group
Control
group Difference (P)
Cohort 1 (both phases)
Total expenditures for
Medicare-covered services 13,845 12,961 884 (0.476) 9,566 8,450 1,116 (0.094)
Medicare Part A 8,446 7,502 945 (0.344) 5,136 4,539 597 (0.247)
Medicare Part B 5,399 5,459 59 (0.870) 4,430 3,911 519 (0.025)
Total intervention-related costs* 8,662 0 NA 8,662 0 NA
Total costs 22,507 12,961 9,546 (0.001) 18,228 8,450 9,778 (0.000)
Cohort 2 (only phase II)
Total expenditures for
Medicare-covered services 11,906 11,661 245 (0.931) 6,450 8,694 2,244 (0.132)
Medicare Part A 7,296 6,886 410 (0.867) 2,991 4,957 1,966 (0.118)
Medicare Part B 4,610 4,775 165 (0.799) 3,458 3,736 278 (0.443)
Total intervention-related costs 8,437 0 NA 8,437 0 NA
Total costs 20,343 11,661 8,682 (0.000) 14,877 8,694 6,183 (0.000)
Sample sizes
Cohort 1 379 358 — 446 442 —
Cohort 2 82 84 — 161 164 —
Data are means, in dollars. Source: IDEATel tracking status ﬁle and 1999–2006 Medicare claims and enrollment records. Means were predicted with ordinary least-
squaresregressionmodels,whichcontrolledforenrollees’baselinecharacteristicsandthepre-enrollmentvalueoftheoutcomemeasure.Estimatesreﬂectannualized
expenditures for the period from each sample member’s randomization through the end of the study follow-up period (31 December 2006). Observations are
weightedbythefractionofthefollow-upperiodthattheenrolleewasaliveandnotinanHMO;expendituresareexcludedduringmonthstheenrolleewasinanHMO
ornotalive.ThreecontrolgroupmembersweredroppedfromtheanalysisinNewYorkCitybecausetheyaremissingcontrolvariablesusedintheregressionanalysis.
See the online appendix for details on the data sources for and construction of the intervention-related cost estimates. *Total intervention-related costs for cohort
1 are based on the arithmetic average of demonstration costs for phase I and phase II, weighted by the average length of time that phase I participants were enrolled
during each phase (see online appendix). NA, not applicable.
Moreno and Associates
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1203deﬁnitively attribute impacts to telemedi-
cine, case management, or both. Several
sensitivity tests were conducted, with no
change in ﬁndings.
CONCLUSIONS — IDEATel’s inter-
vention-related costs were excessive be-
causeofthesizeofthebudgetallocatedto
its operations and the costly HTUs. The
demonstration’s costs were higher than
thecostsofcomparabletelemedicinepro-
grams ($415 to $1,830 per participant
per year) that served people with diabe-
tes, used televisits with nurse case man-
agers and in-home visits, and had the
“potential to effect costs savings” (3,4).
Giventheabsenceofeffectsonservice
use (2), ﬁnding no effects on Medicare
costs was not surprising. The higher
Medicare expenditures for the treatment
group may have been due to chance or
because IDEATel identiﬁed the need for
some health services among medically
underserved beneﬁciaries.
For IDEATel to be cost-effective, the
intervention-related costs would have to
be drastically reduced, while maintaining
clinical impacts. Less expensive tele-
phonic interventions (5,6) and diabetes
case-management programs have yielded
comparable improvements in beneﬁcia-
ries’ clinical outcomes to IDEATel’s im-
pacts (7). Even if intervention costs were
halved and the program reduced hospi-
talizations by 50%, both unlikely scenar-
ios,theprogramwouldstillincreasecosts
to the government.
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